LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

Home・Listă Acțiuni・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Deschisă

SectorSănătate

583.14 -0.47

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

570.81

Maxim

592.54

Indicatori cheie
By Trading Economics
Venit	-72M -114M
Vânzări	74M 287M
EPS	-4.956
Marjă de profit	-39.75
Angajați	528
EBITDA	-75M -114M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	-1.99% downside

Statistici piață
By TradingEconomics
Capitalizare de piață	4B 13B
Deschiderea anterioară	583.61
Închiderea anterioară	583.14

Sentimentul știrilor

By Acuity

23%

77%

49 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

263.2 / 277.1 Suport & Rezistență

Madrigal Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 dec. 2025, 23:21 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec. 2025, 23:14 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec. 2025, 22:01 UTC

Principalele dinamici ale pieței

Costco Wholesale Reports Higher Monthly Sales

3 dec. 2025, 21:38 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec. 2025, 23:10 UTC

Câștiguri

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec. 2025, 23:06 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec. 2025, 22:20 UTC

Câștiguri

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec. 2025, 22:19 UTC

Câștiguri

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec. 2025, 22:17 UTC

Câștiguri

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec. 2025, 22:16 UTC

Câștiguri

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec. 2025, 22:15 UTC

Câștiguri

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec. 2025, 22:09 UTC

Achiziții, Fuziuni, Preluări

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 dec. 2025, 21:49 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:23 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec. 2025, 21:19 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:06 UTC

Câștiguri

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec. 2025, 21:03 UTC

Câștiguri

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparație

Modificare preț

Madrigal Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

-1.99% jos

Prognoză pe 12 luni

Medie 561.73 USD -1.99%

Maxim 650 USD

Minim 445 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMadrigal Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 12 analiști care au acordat evaluări ale acțiunilor Madrigal Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

263.2 / 277.1Suport & Rezistență

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

49 / 374 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.